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Into the Valley of Death: Research to Innovation
Abstract
The pharma industry and academia are increasingly working together, often encouraged by governments, as they seek to bring basic research to the market. This is consistent with newer models of innovation policy which stress interaction between the different agents across the innovation process. We examine this interaction in the UK, the EU and the US in part through several specific examples. They suggest that co-operation is still far from perfect and that academia's return on its research is relatively small. Countries are also beginning to use research as a tool of industrial economic policy.
The phase between research and successful innovation is known as the Valley of Death. The pharma industry and academia are increasingly working together, often encouraged by governments, as they seek to successfully navigate the Valley and bring research to the market. This is consistent with newer models of innovation policy which stress interaction between the different agents across the innovation process. We examine this interaction, in part through several academic research case studies. They suggest that co-operation has been focused on the research stages of innovation and that academia's return on its IPR is relatively small. Countries are also beginning to use research as a tool of industrial economic policy.
The nature of innovation
Until the 1990s the linear model of innovation policy was dominant. This viewed technical change as happening in a linear fashion from invention to innovation to diffusion. The stages of the "Technology Push", version of the original linear model, are: Basic science→Design and engineering→ Manufacturing→ Marketing→ Sales. In this model the role of universities 3 is often fundamental. However, in the past decade a new understanding of the nature of the innovation process has emerged, which emphasizes its systemic and interactive character [1] .
This suggests that innovation should be seen as an evolutionary, non-linear and interactive process, requiring intensive communication and collaboration between firms and organisations such as universities, financial institutions and government agencies. An example of this is the triple helix model which emphasises interaction between university, industry and government [2] and a more system-centred approach to innovation policy [3] .
This does not mean that focusing on basic research and on the technological aspects of innovation is the wrong policy, but that it needs to be complemented with the organisational, financial, skill and commercial aspects of innovation.
In tune with this, the OECD [4] argue that much innovation appears to fail because of a lack of co-ordination and a failure to join up all the agents who are part of the innovation process. Finance is often a key constraining factor. Innovation in the pharma industry, where an aspect of the Valley of Death is the translation gap, is particularly fraught with problems.
Translation may be defined as the transfer of basic biomedical research into clinical interventions. It correlates with the design and engineering stage of the linear model and the problems are substantial. The time-lag between filing a basic patent on a compound and its commercialization as a drug is long at about 11-12 years and only a small fraction of all synthesized compounds finally enter the market [5] . The average cost of taking a drug from concept to market is estimated to be in excess of $1 billion and only 20% of approved drugs make more money than their associated R&D cost [6] . Even then, dangerous side effects may emerge for some drugs after several years of sales. This has led to increasingly stringent regulatory approval guidelines, making an already slow system [7] even slower. Further obstacles to translation are discussed in [8] . All of this often makes funding difficult to obtain, particularly for the early stages of translation research.
The changing roles of firms, universities and governments in the pharmaceutical industry
Translation research can be done either by large pharmaceutical firms, specialist SMEs or universities, often via spin-out companies. In recent years the latter have become increasingly common [9] . Moving away from the linear model, there has also been an increasing tendency for industry, encouraged by government as in the triple helix, to finance and engage with academia at an early stage of research, often in the form of research centres [6] . In part universities welcome such engagement because of increased financial pressures. Traditionally the pharmaceutical industry preferred to keep research in-house [9] . But arguably in the face of rising costs and greater difficulties in finding major new drugs, they too welcome greater collaboration with universities [7] .
Examples from the UK and the USA
Examples from the Medical Research Council
The UK's Medical Research Council (MRC) in its annual reports and associated documents details the economic impact of research it has part-funded. Superficially it tells a good story. 
Other case studies
The other case studies do not relate to the development of new drugs per se, but there are still benefits to the universities and the UK, and they illustrate the diverse aims behind the public funding of university research. Cardiff's research has facilitated the identification and characterisation of a series of genes for major inherited disorders including autosomal recessive colorectal cancer and Huntington's disease. At Exeter and Plymouth, research showed that the most common cause of permanent neonatal diabetes was a mutation(s) residing in a region encoding the pore-forming subunit of a type of potassium channel which senses and responds to alterations in the ratio of ATP:ADP in the beta-cells. Research at Oxford showed that the early risk of a major stroke in the first few days after more minor 'warning' events, was much higher than had previously been supposed and developed simple clinical risk scores to identify high-risk patients.
Finally, at Glasgow a study researched the evidence that smoke-free legislation has a significant impact on heart disease. the move from "first-to-invent" to "first-to-file", by which in the event of multiple patent application files, priority will be given to the one filed first. There are several other aspects to this legislation and it has been described as the biggest change to the US patent system since the 1950s. It has in part been designed to reduce legal challenges to patents, but also brings the US system closer to that of other countries. In doing so it may give an inducement for patents to be files earlier, and this may encourage universities to collaborate with the private sector at an earlier stage.
The Situation in the USA
The NIH in their annual reports seem keen to emphasise that their spending benefits every state and almost every congressional district, rather than the specific impact of spending in keep France in the forefront of pharmaceutical innovation and production [7] . The IMI also supports collaborative research projects and builds networks of industrial and academic experts in Europe. In America, the NIH's Roadmap Initiative also makes some developments in this direction (see http://commonfund.nih.gov/aboutroadmap.aspx), with the specific aim of changing the academic culture to foster collaboration.
Concluding remarks
The process of bringing basic research to successful innovation is changing with closer collaboration between industry, academia and government agencies. At the same time in some cases universities are themselves taking new drugs further down the innovation chain through spin-out companies. All these developments should facilitate the more efficient development of new drugs. They may also help with the provision of venture capital and other funding for translational research in general, and early translational research in particular, which tends to be in short supply. This may then help researchers, universities and government meet their moral, and financial, obligation to translate basic research to clinical validation and benefit.
In addition it is possible that they will lead to universities and industry sharing more equally in the gains from research. The evidence suggests that the income generated from IPR is relatively small compared to the total revenues being generated and the total costs of research. Hence average license income in Europe equals 1.5% of the research expenditures by universities and research institutes and in the US it is 4% (see http://www.knowledgetransfer-study.eu). Of course, not all research is intended to directly generate revenue, but the examples we gave earlier suggest that universities and their funders are selling their IPR too cheaply. The work behind some of these case studies has taken over 30 years, mainly funded minimally by research grants and the universities have failed to be effectively compensated when these are successfully commercialised.
However, it is not obviously the case that this integrated approach to university research involving multiple partners will improve the universities' position in this respect. 
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There are also ethical problems involved with this new approach. Firstly it clashes with academia's traditional focus on disseminating knowledge as widely and freely as possible, and risks taking the focus away from high quality research publications [10] . Possibly in an attempt to protect themselves from criticism, some universities are seeking to ensure that products from their IPR are marketed under favorable conditions to the developing world.
These include Boston, British Colombia, Brown, Edinburgh, Emory, Oxford, Washington, Yale and UCL. Secondly, it involves, directly or indirectly, public money underwriting the commercial success of some firms and not others.
This use of public money is being done not just to promote research per se, but increasingly as a tool of industrial and economic policy, as in France, with their poles of excellence, Germany and more widely the EU. Even in the US, where there has been a traditionally reliance on market forces, the NIH is beginning to view research as a way of boosting the economy and has long, implicitly sought to strengthen the global position of American companies. However it is also often the case, as in the UK, that the firms benefitting from the research are foreign based multinationals and hence the boost is to other economies. In this context, certainly within the UK, greater domestic support for candidate translation is required to help avoid migration to other countries with greater funding.
